Clinical Trials Logo

Bilateral Nasal Polyposis clinical trials

View clinical trials related to Bilateral Nasal Polyposis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03688555 Completed - Clinical trials for Bilateral Nasal Polyposis

A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis

Start date: October 19, 2018
Phase: Phase 2
Study type: Interventional

The study will evaluate the effect of ACT-774312 on the nasal polyps and will assess the safety and tolerability of ACT-774312 in the patients with bilateral nasal polyposis

NCT ID: NCT01624662 Completed - Clinical trials for Bilateral Nasal Polyposis

Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device

Start date: October 30, 2013
Phase: Phase 3
Study type: Interventional

The primary objective of this study was to compare the efficacy of intranasal administration of 100, 200, and 400 μg twice daily (bid) of fluticasone propionate, delivered by the Optinose device, with matching placebo in subjects with bilateral nasal polyposis and nasal congestion.

NCT ID: NCT01622569 Completed - Clinical trials for Bilateral Nasal Polyposis

Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety

Start date: November 19, 2013
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to compare the efficacy of intranasal administration of 100, 200, and 400 μg of fluticasone propionate twice a day delivered by the OptiNose device with placebo in subjects with bilateral nasal polyposis. Two co-primary endpoints will be used in the study: reduction of nasal congestion/obstruction symptoms at the end of Week 4 of the double-blind treatment phase measured by the 7 day average instantaneous AM diary symptom scores, and reduction in total polyp grade (sum of scores from both nasal cavities) over the 16 weeks of the double-blind treatment phase as determined by the Lildholdt scale score measured by nasoendoscopy.